

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

(b) On December 4, 2012, the Board of Directors of Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), approved a change in the Company's fiscal year end from August 31 to December 31. As a result of this change, the Company will file a transition report on Form 10-K for the four-month period ended December 31, 2012. The Company expects to file the transition report on or about March 15, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RAPTOR PHARMACEUTICAL CORP.

Date: December 7, 2012 By: /s/ Christopher M. Starr, Ph.D.
Name: Christopher M. Starr, Ph.D.
Title: Chief Executive Officer and Director